Related Experiment Video
Updated: Oct 7, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
COVID-19 and chronic kidney disease: an updated overview of reviews
Sara S Jdiaa1, Razan Mansour2, Abdallah El Alayli2
1Division of Nephrology, University of Toronto, Toronto, ON, Canada.
Insights
Chronic Kidney Disease (CKD) significantly increases the risk of hospitalization and mortality in patients with COVID-19. Identifying preventative strategies for this vulnerable population is crucial.
Area of Science:
- Nephrology
- Infectious Diseases
- Public Health
Background:
- Coronavirus disease (COVID-19) has caused over 3.5 million deaths globally.
- Comorbidities, such as Chronic Kidney Disease (CKD), significantly impact COVID-19 outcomes.
- This study assesses the effect of CKD on COVID-19 contraction, hospitalization, mortality, and severity.
Purpose of the Study:
- To evaluate the impact of Chronic Kidney Disease (CKD) on COVID-19 outcomes.
- To synthesize evidence on CKD's association with COVID-19 hospitalization, mortality, and severity.
- To inform preventative strategies for individuals with CKD.
Main Methods:
- An overview of systematic reviews and primary studies was conducted.
- Searches included published and preprint databases, with updates for studies post-August 2020.
- Review quality was assessed using the AMSTAR tool.
Main Results:
- Sixty-nine systematic reviews and 66 primary studies were included.
- Prevalence of CKD in COVID-19 patients ranged from 0.4% to 49.0%.
- CKD was associated with increased hospitalization (RR=1.63) and mortality (HR=1.48, OR=1.77) in COVID-19 patients.
Conclusions:
- Chronic Kidney Disease (CKD) is linked to adverse outcomes in COVID-19 patients.
- There is a critical need for targeted prevention strategies for COVID-19 in individuals with CKD.
Background:
Coronavirus disease (COVID-19) has resulted in the death of more than 3.5 million people worldwide. While COVID-19 mostly affects the lungs, different comorbidities can have an impact on its outcomes. We performed an overview of reviews to assess the effect of Chronic Kidney Disease (CKD) on contracting COVID-19, hospitalization, mortality, and disease severity.
Methods:
We searched published and preprint databases. We updated the reviews by searching for primary studies published after August 2020, and prioritized reviews that are most updated and of higher quality using the AMSTAR tool.
Results:
We included 69 systematic reviews and 66 primary studies. Twenty-eight reviews reported on the prevalence of CKD among patients with COVID-19, which ranged from 0.4 to 49.0%. One systematic review showed an increased risk of hospitalization in patients with CKD and COVID-19 (RR = 1.63, 95% CI 1.03-2.58) (Moderate certainty). Primary studies also showed a statistically significant increase of hospitalization in such patients. Thirty-seven systematic reviews assessed mortality risk in patients with CKD and COVID-19. The pooled estimates from primary studies for mortality in patients with CKD and COVID-19 showed a HR of 1.48 (95% CI 1.33-1.65) (Moderate certainty), an OR of 1.77 (95% CI 1.54-2.02) (Moderate certainty) and a RR of 1.6 (95% CI 0.88-2.92) (Low certainty).
Conclusions:
Our review highlights the impact of CKD on the poor outcomes of COVID-19, underscoring the importance of identifying strategies to prevent COVID-19 infection among patients with CKD.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction

